vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Tronox Holdings plc (TROX). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $730.0M, roughly 1.3× Tronox Holdings plc). Astrana Health, Inc. runs the higher net margin — 0.7% vs -24.1%, a 24.8% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 8.0%). Tronox Holdings plc produced more free cash flow last quarter ($53.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -2.9%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Tronox Limited is an American worldwide chemical company involved in the titanium products industry with approximately 6,500 employees. Following its acquisition of the mineral sands business formerly belonging to South Africa's Exxaro Resources, Tronox is the largest fully integrated seller and marketer of titanium dioxide (TiO2) pigment, which provides brightness to applications such as coatings, plastics and paper. Tronox mines titanium-bearing mineral sands and operates upgrading faciliti...

ASTH vs TROX — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.3× larger
ASTH
$950.5M
$730.0M
TROX
Growing faster (revenue YoY)
ASTH
ASTH
+34.9% gap
ASTH
42.9%
8.0%
TROX
Higher net margin
ASTH
ASTH
24.8% more per $
ASTH
0.7%
-24.1%
TROX
More free cash flow
TROX
TROX
$59.0M more FCF
TROX
$53.0M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-2.9%
TROX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
TROX
TROX
Revenue
$950.5M
$730.0M
Net Profit
$6.6M
$-176.0M
Gross Margin
5.3%
Operating Margin
1.9%
-15.6%
Net Margin
0.7%
-24.1%
Revenue YoY
42.9%
8.0%
Net Profit YoY
184.4%
-486.7%
EPS (diluted)
$0.12
$-1.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
TROX
TROX
Q4 25
$950.5M
$730.0M
Q3 25
$956.0M
$699.0M
Q2 25
$654.8M
$731.0M
Q1 25
$620.4M
$738.0M
Q4 24
$665.2M
$676.0M
Q3 24
$478.7M
$804.0M
Q2 24
$486.3M
$820.0M
Q1 24
$404.4M
$774.0M
Net Profit
ASTH
ASTH
TROX
TROX
Q4 25
$6.6M
$-176.0M
Q3 25
$373.0K
$-99.0M
Q2 25
$9.4M
$-84.0M
Q1 25
$6.7M
$-111.0M
Q4 24
$-7.8M
$-30.0M
Q3 24
$16.1M
$-25.0M
Q2 24
$19.2M
$16.0M
Q1 24
$14.8M
$-9.0M
Gross Margin
ASTH
ASTH
TROX
TROX
Q4 25
5.3%
Q3 25
7.4%
Q2 25
10.8%
Q1 25
13.4%
Q4 24
17.3%
Q3 24
15.9%
Q2 24
18.3%
Q1 24
15.5%
Operating Margin
ASTH
ASTH
TROX
TROX
Q4 25
1.9%
-15.6%
Q3 25
2.0%
-6.2%
Q2 25
3.1%
-4.8%
Q1 25
3.3%
-8.3%
Q4 24
0.1%
7.1%
Q3 24
5.9%
6.7%
Q2 24
6.2%
9.3%
Q1 24
7.5%
5.3%
Net Margin
ASTH
ASTH
TROX
TROX
Q4 25
0.7%
-24.1%
Q3 25
0.0%
-14.2%
Q2 25
1.4%
-11.5%
Q1 25
1.1%
-15.0%
Q4 24
-1.2%
-4.4%
Q3 24
3.4%
-3.1%
Q2 24
3.9%
2.0%
Q1 24
3.7%
-1.2%
EPS (diluted)
ASTH
ASTH
TROX
TROX
Q4 25
$0.12
$-1.11
Q3 25
$0.01
$-0.63
Q2 25
$0.19
$-0.53
Q1 25
$0.14
$-0.70
Q4 24
$-0.14
$-0.19
Q3 24
$0.33
$-0.16
Q2 24
$0.40
$0.10
Q1 24
$0.31
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
TROX
TROX
Cash + ST InvestmentsLiquidity on hand
$429.5M
$199.0M
Total DebtLower is stronger
$3.1B
Stockholders' EquityBook value
$779.3M
$1.4B
Total Assets
$2.2B
$6.2B
Debt / EquityLower = less leverage
2.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
TROX
TROX
Q4 25
$429.5M
$199.0M
Q3 25
$463.4M
$185.0M
Q2 25
$342.1M
$132.0M
Q1 25
$260.9M
$138.0M
Q4 24
$290.8M
$151.0M
Q3 24
$350.3M
$167.0M
Q2 24
$327.7M
$201.0M
Q1 24
$337.3M
$152.0M
Total Debt
ASTH
ASTH
TROX
TROX
Q4 25
$3.1B
Q3 25
$3.1B
Q2 25
$2.7B
Q1 25
$2.8B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.8B
Q1 24
$2.8B
Stockholders' Equity
ASTH
ASTH
TROX
TROX
Q4 25
$779.3M
$1.4B
Q3 25
$775.5M
$1.6B
Q2 25
$765.5M
$1.6B
Q1 25
$745.4M
$1.7B
Q4 24
$712.7M
$1.8B
Q3 24
$704.6M
$1.9B
Q2 24
$678.9M
$1.9B
Q1 24
$653.5M
$1.9B
Total Assets
ASTH
ASTH
TROX
TROX
Q4 25
$2.2B
$6.2B
Q3 25
$2.2B
$6.3B
Q2 25
$1.4B
$6.2B
Q1 25
$1.3B
$6.1B
Q4 24
$1.4B
$6.0B
Q3 24
$1.3B
$6.2B
Q2 24
$1.3B
$6.1B
Q1 24
$1.2B
$6.0B
Debt / Equity
ASTH
ASTH
TROX
TROX
Q4 25
2.21×
Q3 25
2.01×
Q2 25
1.67×
Q1 25
1.64×
Q4 24
1.57×
Q3 24
1.45×
Q2 24
1.47×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
TROX
TROX
Operating Cash FlowLast quarter
$-2.9M
$121.0M
Free Cash FlowOCF − Capex
$-6.0M
$53.0M
FCF MarginFCF / Revenue
-0.6%
7.3%
Capex IntensityCapex / Revenue
0.3%
9.3%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$-281.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
TROX
TROX
Q4 25
$-2.9M
$121.0M
Q3 25
$10.0M
$-57.0M
Q2 25
$90.9M
$28.0M
Q1 25
$16.6M
$-32.0M
Q4 24
$-10.9M
$82.0M
Q3 24
$34.0M
$87.0M
Q2 24
$23.2M
$160.0M
Q1 24
$6.0M
$-29.0M
Free Cash Flow
ASTH
ASTH
TROX
TROX
Q4 25
$-6.0M
$53.0M
Q3 25
$7.4M
$-137.0M
Q2 25
$89.5M
$-55.0M
Q1 25
$13.6M
$-142.0M
Q4 24
$-13.5M
$-35.0M
Q3 24
$31.7M
$-14.0M
Q2 24
$20.4M
$84.0M
Q1 24
$5.6M
$-105.0M
FCF Margin
ASTH
ASTH
TROX
TROX
Q4 25
-0.6%
7.3%
Q3 25
0.8%
-19.6%
Q2 25
13.7%
-7.5%
Q1 25
2.2%
-19.2%
Q4 24
-2.0%
-5.2%
Q3 24
6.6%
-1.7%
Q2 24
4.2%
10.2%
Q1 24
1.4%
-13.6%
Capex Intensity
ASTH
ASTH
TROX
TROX
Q4 25
0.3%
9.3%
Q3 25
0.3%
11.4%
Q2 25
0.2%
11.4%
Q1 25
0.5%
14.9%
Q4 24
0.4%
17.3%
Q3 24
0.5%
12.6%
Q2 24
0.6%
9.3%
Q1 24
0.1%
9.8%
Cash Conversion
ASTH
ASTH
TROX
TROX
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
10.00×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

TROX
TROX

Ti O2$577.0M79%
Zircon$78.0M11%
Idle Facility And Lower Of Cost Or Net Realizable Value Charges$42.0M6%
Other$20.0M3%
MGT$13.0M2%

Related Comparisons